Publications by authors named "David Einstein"

Claim this Profile
N
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.
Fen Ma, Sen Chen, Luigi Cecchi, Betul Ersoy-Fazlioglu, Joshua W Russo, David J Einstein

J Clin Invest· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.
Jude Owiredu, Betul Ersoy-Fazlioglu, Larysa Poluben, Carla Calagua, Christopher Dennehy, David J Einstein

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol.
Rebekah L Wilson, Anderson Vulczak, Alicia K Morgans, Mary Norris, Jocelyn Greer, David J Einstein

Front Sports Act Living· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating Drug Development in Hormone-Naïve Prostate Cancer Through Multi-Modal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Deaglan McHugh, Matthew Dallos, Min Yuen Teo, Sean M McBride, Anuradha Gopalan, David J Einstein

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer.
Sheng-Yu Ku, Nishat Manzar, Maria Mica Garcia, Min Jin Kim, David J Einstein

Mol Cancer Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.
Prathyusha Konda, Cary N Weiss, Yantong Cui, Sayed Matar, Jinyu Wang, David J Einstein

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exercise to enhance cardiovascular health among black men with prostate cancer with androgen deprivation therapy (the POWER trial): A study protocol.
Dong-Woo Kang, Salvatore Ficarra, Rebekah L Wilson, Alicia K Morgans, Paul L Nguyen, David J Einstein

Contemp Clin Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Kei Mizuno, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, Martin K Bakht, Michael Sigouros, David Einstein

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Jasmonate-induced prey response in the carnivorous plant .
Zane G Long, Gemma R Takahashi, Franchesca M Cumpio, Omar J Akbari, Ulysses Castelan, David E Einstein, Elliott E Einstein

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.
Fen Ma, Sen Chen, Luigi Cecchi, Betul Ersoy-Fazlioglu, Joshua Russo, David Einstein

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer.
Praful Ravi, Lucia Kwak, Andres M Acosta, Saahil Rastogi, Wanling Xie, David J Einstein

Eur Urol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life.
Daniel Sentana-Lledo, Amelia Barnett, David J Einstein, Arjun Gupta, Alicia K Morgans

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Andreas Varkaris, Keshan Wang, Mannan Nouri, Nina Kozlova, Daniel R Schmidt, David J Einstein

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?
Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein

Curr Oncol Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to B. Tombal et al.
David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.
Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L Dalrymple, Christopher M Dennehy, David J Einstein

Mol Cancer Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy.
David J Einstein, Brian Halbert, Thomas Denize, Sayed Matar, Destiny J West

J Immunother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma.
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, Fiona McBride, Jiao Li, David J Einstein

Cell· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methane-derived microbial biostimulant reduces greenhouse gas emissions and improves rice yield.
Sarma Rajeev Kumar, Einstein Mariya David, Gangigere Jagadish Pavithra, Gopalakrishnan Sajith Kumar, Kuppan Lesharadevi

Front Plant Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.
Henri Leinonen, Jianye Zhang, Laurence M Occelli, Umair Seemab, Elliot H Choi, Elliott E Einstein, David E Einstein

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
David J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, Ravi A Madan

Curr Opin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dominant role for pigment epithelial CRALBP in supplying visual chromophore to photoreceptors.
Marco Bassetto, Alexander V Kolesnikov, Dominik Lewandowski, Jianying Z Kiser, Maximilian Halabi, David E Einstein

Cell Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, David Einstein

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis